Imatinib Mesylate

Curated

← predicts response to

ABL1 G250ESNV

resistance

Curated

← predicts response to

ABL1 Y253HSNV

resistance

Curated

← predicts response to

ABL1 V299LSNV

resistance

Curated

← predicts response to

ABL1 Fusionfusion

33 source records aggregated

resistance

Curated

← predicts response to

ABL1 F359VSNV

3 source records aggregated

resistance

Curated

← predicts response to

ABL1 E255KSNV

3 source records aggregated

resistance

Curated

← predicts response to

ABL1 F359CSNV

3 source records aggregated

resistance

Curated

← predicts response to

ABL1 F317LSNV

2 source records aggregated

resistance

Curated

← predicts response to

ABL1 M244VSNV

2 source records aggregated

resistance

Curated

← predicts response to

ABL1 T315ISNV

2 source records aggregated

resistance

Curated

← predicts response to

ABL1 M351TSNV

2 source records aggregated

resistance

Curated

← predicts response to

ABL1 E255VSNV

2 source records aggregated

resistance

Curated

← predicts response to

ABL1 Y253HSNV

2 source records aggregated

resistance

Curated

← predicts response to

ABL1 E459KSNV

resistance

Curated

← predicts response to

ABL1 L248VSNV

resistance

Curated

← predicts response to

ABL1 E355GSNV

resistance

Curated

← predicts response to

ABL1 A397PSNV

resistance

Curated

← predicts response to

ABL1 H396RSNV

resistance

Curated

← predicts response to

ABL1 F486SSNV

resistance

Curated

← predicts response to

ABL1 F359ISNV

resistance

Curated

← predicts response to

ABL1 Q300RSNV

resistance

Curated

← predicts response to

ABL1 L387FSNV

resistance

Curated

← predicts response to

ABL1 E453ASNV

resistance

Curated

← predicts response to

ABL1 N336SSNV

resistance

Curated

← predicts response to

ABL1 C475Vsplice

resistance

Curated

← predicts response to

ABL1 V379ISNV

resistance

Curated

B Lymphoblastic Leukemia/Lymphoma

← predicts response to

ABL1 Fusionfusion

sensitivity

Curated

← predicts response to

ABL1 Fusionfusion

31 source records aggregated

resistance

Curated

← predicts response to

ABL1 E255KSNV

4 source records aggregated

resistance

Curated

← predicts response to

ABL1 T315ISNV

4 source records aggregated

resistance

Curated

← predicts response to

ABL1 L248RSNV

2 source records aggregated

resistance

Curated

← predicts response to

ABL1 F359CSNV

2 source records aggregated

resistance

Curated

← predicts response to

ABL1 Y253HSNV

2 source records aggregated

resistance

Curated

← predicts response to

ABL1 L248VSNV

2 source records aggregated

resistance

Curated

← predicts response to

ABL1 L384MSNV

resistance

Curated

← predicts response to

ABL1 H396RSNV

resistance

Curated

← predicts response to

ABL1 V379ISNV

resistance

Curated

← predicts response to

ABL1 F359VSNV

resistance

Curated

← predicts response to

ABL1 E355GSNV

resistance

Curated

← predicts response to

ABL1 M351TSNV

resistance

Curated

← predicts response to

ABL1 F317LSNV

resistance

Curated

← predicts response to

ABL1 D276GSNV

resistance

Curated

← predicts response to

ABL1 Q252HSNV

resistance

Curated

← predicts response to

ABL1 G250ESNV

resistance

Curated

← predicts response to

ABL1 M244VSNV

resistance

Curated

← predicts response to

ABL1 V299LSNV

resistance

Curated

← predicts response to

ABL1 H396PSNV

resistance

Curated

← predicts response to

ABL1 F311LSNV

resistance

Curated

← predicts response to

KIT V560DSNV

sensitivity

Malignant Neoplasm

Curated

← predicts response to

resistance

Curated

← predicts response to

ABL1 E255VSNV

resistance

Curated

Lung Non-Small Cell Carcinoma

← predicts response to

ABL1 G340LSNV

sensitivity

Curated

Imatinib Mesylate targets …TARGETS4 of 4
→ targets	BCR	—	INHIBITOR	—	1	Curated	chembl	graph →
→ targets	KIT	—	INHIBITOR	—	1	Curated	chembl	graph →
→ targets	PDGFRB	—	INHIBITOR	—	1	Curated	chembl	graph →
→ targets	ABL1	—	INHIBITOR	—	1	Curated	chembl	graph →

Imatinib Mesylate targets …TARGETS4 of 4

→ targets

BCR

—

INHIBITOR

—

Curated

→ targets

KIT

—

INHIBITOR

—

Curated

→ targets

PDGFRB

—

INHIBITOR

—

Curated

→ targets

ABL1

—

INHIBITOR

—

Curated

Imatinib Mesylate investigated for …INVESTIGATED_FOR15 of 67show all (up to 200)
→ investigated for	Chronic Myeloid Leukemia, BCR-ABL1 Positivemolecular_subtype 3 source records aggregated	supports	B	Chronic Myeloid Leukemia, BCR-ABL1 Positive	3	Curated	civic	graph →
→ investigated for	Myelodysplastic/Myeloproliferative Neoplasmhematologic_malignancy	unknown	4	Myelodysplastic/Myeloproliferative Neoplasm	1	Curated	chembl	graph →
→ investigated for	Dermatofibrosarcoma Protuberanssubtype	unknown	4	Dermatofibrosarcoma Protuberans	1	Curated	chembl	graph →
→ investigated for	Gastrointestinal Stromal Tumorsubtype	unknown	4	Gastrointestinal Stromal Tumor	1	Curated	chembl	graph →
→ investigated for	Acute Lymphoblastic Leukemiahematologic_malignancy	unknown	4	Acute Lymphoblastic Leukemia	1	Curated	chembl	graph →
→ investigated for	Chronic Myeloid Leukemia, BCR-ABL1 Positivemolecular_subtype	unknown	4	Chronic Myeloid Leukemia, BCR-ABL1 Positive	1	Curated	chembl	graph →
→ investigated for	Chronic Myeloid Leukemia, BCR-ABL1 Positivemolecular_subtype 34 source records aggregated	supports	C	Chronic Myeloid Leukemia, BCR-ABL1 Positive	34	Curated	civic	graph →
→ investigated for	B Lymphoblastic Leukemia/Lymphomahematologic_malignancy	supports	C	B Lymphoblastic Leukemia/Lymphoma	1	Curated	civic	graph →
→ investigated for	Astrocytic Tumorsubtype	unknown	3	Astrocytic Tumor	1	Curated	chembl	graph →
→ investigated for	Myeloid Leukemiahematologic_malignancy	unknown	3	Myeloid Leukemia	1	Curated	chembl	graph →
→ investigated for	Acute Biphenotypic Leukemiahematologic_malignancy	unknown	3	Acute Biphenotypic Leukemia	1	Curated	chembl	graph →
→ investigated for	Lymphoid Leukemiahematologic_malignancy	unknown	3	Lymphoid Leukemia	1	Curated	chembl	graph →
→ investigated for	Glioblastomasubtype	unknown	3	Glioblastoma	1	Curated	chembl	graph →
→ investigated for	Neoplasmcancer_family	unknown	3	Neoplasm	1	Curated	chembl	graph →
→ investigated for	Leukemiacancer_family	unknown	3	Leukemia	1	Curated	chembl	graph →

Imatinib Mesylate investigated for …INVESTIGATED_FOR15 of 67show all (up to 200)

→ investigated for

Chronic Myeloid Leukemia, BCR-ABL1 Positivemolecular_subtype

3 source records aggregated

supports

Curated

Myelodysplastic/Myeloproliferative Neoplasm

→ investigated for

Myelodysplastic/Myeloproliferative Neoplasmhematologic_malignancy

unknown

Curated

Dermatofibrosarcoma Protuberans

→ investigated for

Dermatofibrosarcoma Protuberanssubtype

unknown

Curated

Gastrointestinal Stromal Tumor

→ investigated for

Gastrointestinal Stromal Tumorsubtype

unknown

Curated

Acute Lymphoblastic Leukemia

→ investigated for

Acute Lymphoblastic Leukemiahematologic_malignancy

unknown

Curated

→ investigated for

Chronic Myeloid Leukemia, BCR-ABL1 Positivemolecular_subtype

unknown

Curated

→ investigated for

Chronic Myeloid Leukemia, BCR-ABL1 Positivemolecular_subtype

34 source records aggregated

supports

Curated

B Lymphoblastic Leukemia/Lymphoma

→ investigated for

B Lymphoblastic Leukemia/Lymphomahematologic_malignancy

supports

Curated

→ investigated for

Astrocytic Tumorsubtype

unknown

Astrocytic Tumor

Curated

→ investigated for

Myeloid Leukemiahematologic_malignancy

unknown

Myeloid Leukemia

Curated

Acute Biphenotypic Leukemia

→ investigated for

Acute Biphenotypic Leukemiahematologic_malignancy

unknown

Curated

→ investigated for

Lymphoid Leukemiahematologic_malignancy

unknown

Lymphoid Leukemia

Curated

→ investigated for

Glioblastomasubtype

unknown

Glioblastoma

Curated

→ investigated for

Neoplasmcancer_family

unknown

Neoplasm

Curated

→ investigated for

Leukemiacancer_family

unknown

Curated

Imatinib Mesylate investigated in trials for …INVESTIGATED_IN_TRIALSderived15 of 142show all (up to 200)
→ investigated in trials for	Leukemiacancer_family 41 trials (0 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Leukemia	41	Observed	clinicaltrials	graph →
→ investigated in trials for	Gastrointestinal Stromal Tumorsubtype 32 trials (2 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Gastrointestinal Stromal Tumor	32	Observed	clinicaltrials	graph →
→ investigated in trials for	Chronic Myeloid Leukemia, BCR-ABL1 Positivemolecular_subtype 16 trials (1 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Chronic Myeloid Leukemia, BCR-ABL1 Positive	16	Observed	clinicaltrials	graph →
→ investigated in trials for	Adult Acute Lymphoblastic Leukemia 7 trials (0 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Adult Acute Lymphoblastic Leukemia	7	Observed	clinicaltrials	graph →
→ investigated in trials for	Blast Phase Chronic Myeloid Leukemia, BCR-ABL1 Positive 7 trials (0 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Blast Phase Chronic Myeloid Leukemia, BCR-ABL1 Positive	7	Observed	clinicaltrials	graph →
→ investigated in trials for	Adult Solid Neoplasm 6 trials (0 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Adult Solid Neoplasm	6	Observed	clinicaltrials	graph →
→ investigated in trials for	Chronic Phase Chronic Myeloid Leukemia, BCR-ABL1 Positive 6 trials (1 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Chronic Phase Chronic Myeloid Leukemia, BCR-ABL1 Positive	6	Observed	clinicaltrials	graph →
→ investigated in trials for	Malignant Prostate Neoplasm 6 trials (0 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Malignant Prostate Neoplasm	6	Observed	clinicaltrials	graph →
→ investigated in trials for	Sarcoma 6 trials (0 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Sarcoma	6	Observed	clinicaltrials	graph →
→ investigated in trials for	Childhood Acute Lymphoblastic Leukemia 5 trials (0 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Childhood Acute Lymphoblastic Leukemia	5	Observed	clinicaltrials	graph →
→ investigated in trials for	Myeloid Leukemiahematologic_malignancy 5 trials (0 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Myeloid Leukemia	5	Observed	clinicaltrials	graph →
→ investigated in trials for	Accelerated Phase Chronic Myeloid Leukemia, BCR-ABL1 Positive 4 trials (0 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Accelerated Phase Chronic Myeloid Leukemia, BCR-ABL1 Positive	4	Observed	clinicaltrials	graph →
→ investigated in trials for	Chronic Myelomonocytic Leukemia 4 trials (0 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Chronic Myelomonocytic Leukemia	4	Observed	clinicaltrials	graph →
→ investigated in trials for	Malignant Breast Neoplasm 4 trials (0 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Malignant Breast Neoplasm	4	Observed	clinicaltrials	graph →
→ investigated in trials for	Malignant Lung Neoplasm 4 trials (0 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Malignant Lung Neoplasm	4	Observed	clinicaltrials	graph →

Imatinib Mesylate investigated in trials for …INVESTIGATED_IN_TRIALSderived15 of 142show all (up to 200)

→ investigated in trials for

Leukemiacancer_family

41 trials (0 active) · conditions mapped to this cancer only (no hierarchy roll-up)

—

Observed

Gastrointestinal Stromal Tumor

→ investigated in trials for

Gastrointestinal Stromal Tumorsubtype

32 trials (2 active) · conditions mapped to this cancer only (no hierarchy roll-up)

—

Observed

→ investigated in trials for

Chronic Myeloid Leukemia, BCR-ABL1 Positivemolecular_subtype

16 trials (1 active) · conditions mapped to this cancer only (no hierarchy roll-up)

—

Observed

Adult Acute Lymphoblastic Leukemia

→ investigated in trials for

7 trials (0 active) · conditions mapped to this cancer only (no hierarchy roll-up)

—

Adult Acute Lymphoblastic Leukemia

Observed

Blast Phase Chronic Myeloid Leukemia, BCR-ABL1 Positive

→ investigated in trials for

7 trials (0 active) · conditions mapped to this cancer only (no hierarchy roll-up)

—

Blast Phase Chronic Myeloid Leukemia, BCR-ABL1 Positive

Observed

→ investigated in trials for

Adult Solid Neoplasm

6 trials (0 active) · conditions mapped to this cancer only (no hierarchy roll-up)

—

Adult Solid Neoplasm

Observed

Chronic Phase Chronic Myeloid Leukemia, BCR-ABL1 Positive

→ investigated in trials for

6 trials (1 active) · conditions mapped to this cancer only (no hierarchy roll-up)

—

Chronic Phase Chronic Myeloid Leukemia, BCR-ABL1 Positive

Observed

Malignant Prostate Neoplasm

→ investigated in trials for

6 trials (0 active) · conditions mapped to this cancer only (no hierarchy roll-up)

—

Malignant Prostate Neoplasm

Observed

→ investigated in trials for

Sarcoma

6 trials (0 active) · conditions mapped to this cancer only (no hierarchy roll-up)

—

Sarcoma

Observed

Childhood Acute Lymphoblastic Leukemia

→ investigated in trials for

5 trials (0 active) · conditions mapped to this cancer only (no hierarchy roll-up)

—

Childhood Acute Lymphoblastic Leukemia

Observed

→ investigated in trials for

Myeloid Leukemiahematologic_malignancy

5 trials (0 active) · conditions mapped to this cancer only (no hierarchy roll-up)

—

Myeloid Leukemia

Observed

Accelerated Phase Chronic Myeloid Leukemia, BCR-ABL1 Positive

→ investigated in trials for

4 trials (0 active) · conditions mapped to this cancer only (no hierarchy roll-up)

—

Accelerated Phase Chronic Myeloid Leukemia, BCR-ABL1 Positive

Observed

Chronic Myelomonocytic Leukemia

→ investigated in trials for

4 trials (0 active) · conditions mapped to this cancer only (no hierarchy roll-up)

—

Chronic Myelomonocytic Leukemia

Observed

Malignant Breast Neoplasm

→ investigated in trials for

4 trials (0 active) · conditions mapped to this cancer only (no hierarchy roll-up)

—

Malignant Breast Neoplasm

Observed

→ investigated in trials for

Malignant Lung Neoplasm

4 trials (0 active) · conditions mapped to this cancer only (no hierarchy roll-up)

—

Malignant Lung Neoplasm

Observed

Chronic Phase Chronic Myeloid Leukemia, BCR-ABL1 Positive

Imatinib Mesylate studied in …STUDIED_INderived10 of 188show all (up to 200)
→ studied in	NCT03516279Phase 2 · active not recruiting Pembrolizumab and Dasatinib, Imatinib Mesylate, or Nilotinib in Treating Patients With Chronic Myeloid Leukemia and Persistently Detectable Minimal Residual Disease · 188 trials list this drug (6 active)	—	—	Chronic Phase Chronic Myeloid Leukemia, BCR-ABL1 Positive	1	Observed	clinicaltrials	graph →
→ studied in	NCT00070499Phase 2 · active not recruiting Imatinib Mesylate or Dasatinib in Treating Patients With Previously Untreated Chronic Phase Chronic Myelogenous Leukemia · 188 trials list this drug (6 active)	—	—	Chronic Myeloid Leukemia, BCR-ABL1 Positive	1	Observed	clinicaltrials	graph →
→ studied in	NCT03007147Phase 3 · active not recruiting Imatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia · 188 trials list this drug (6 active)	—	—	Acute Lymphoblastic Leukemia,B Acute Lymphoblastic Leukemia,T Acute Lymphoblastic Leukemia+1	1	Observed	clinicaltrials	graph →
→ studied in	NCT01742299Phase 4 · completed Study to Allow Access to Imatinib for Patients Who Are on Imatinib Treatment in a Novartis-sponsored Study and Are Benefiting From the Treatment as Judged by the Investigator · 188 trials list this drug (6 active)	—	—	not mapped	1	Observed	clinicaltrials	graph →
→ studied in	NCT06655246Phase 1 · recruiting A Study of Ziftomenib in Combination With Imatinib in Patients With Advanced Gastrointestinal Stromal Tumors (GIST) · 188 trials list this drug (6 active)	—	—	Gastrointestinal Stromal Tumor,Malignant Gastrointestinal Stromal Tumor	1	Observed	clinicaltrials	graph →
→ studied in	NCT00015847Phase 2 · terminated Imatinib Mesylate and Interferon Alfa in Treating Patients With Chronic Myelogenous Leukemia · 188 trials list this drug (6 active)	—	—	Leukemia	1	Observed	clinicaltrials	graph →
→ studied in	NCT05385549Phase 2 · recruiting 5 Years of Adjuvant Imatinib in Patients With Gastrointestinal Stromal Tumor With a High Risk · 188 trials list this drug (6 active)	—	—	Gastrointestinal Stromal Tumor	1	Observed	clinicaltrials	graph →
→ studied in	NCT01751425Phase 1 · terminated Ruxolitinib in Treating Participants With Chronic Myeloid Leukemia With Minimal Residual Disease While on Therapy With Tyrosine Kinase Inhibitors · 188 trials list this drug (6 active)	—	—	Chronic Myeloid Leukemia, BCR-ABL1 Positive,Chronic Myeloid Leukemia, Philadelphia Chromosome Positive, BCR-ABL1 Positive	1	Observed	clinicaltrials	graph →
→ studied in	NCT01085617completed Standard Chemotherapy with or Without Nelarabine or Rituximab in Treating Patients with Newly Diagnosed Acute Lymphoblastic Leukemia · 188 trials list this drug (6 active)	—	—	Leukemia	1	Observed	clinicaltrials	graph →
→ studied in	NCT00483366Phase 1 · completed Imatinib Mesylate, Gemcitabine, and Capecitabine in Treating Patients With Advanced Solid Tumors · 188 trials list this drug (6 active)	—	—	Adult Solid Neoplasm	1	Observed	clinicaltrials	graph →

Imatinib Mesylate studied in …STUDIED_INderived10 of 188show all (up to 200)

→ studied in

NCT03516279Phase 2 · active not recruiting

Pembrolizumab and Dasatinib, Imatinib Mesylate, or Nilotinib in Treating Patients With Chronic Myeloid Leukemia and Persistently Detectable Minimal Residual Disease · 188 trials list this drug (6 active)

—

Observed

→ studied in

NCT00070499Phase 2 · active not recruiting

Imatinib Mesylate or Dasatinib in Treating Patients With Previously Untreated Chronic Phase Chronic Myelogenous Leukemia · 188 trials list this drug (6 active)

—

Observed

Acute Lymphoblastic Leukemia,B Acute Lymphoblastic Leukemia,T Acute Lymphoblastic Leukemia+1

→ studied in

NCT03007147Phase 3 · active not recruiting

Imatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia · 188 trials list this drug (6 active)

—

Observed

→ studied in

NCT01742299Phase 4 · completed

Study to Allow Access to Imatinib for Patients Who Are on Imatinib Treatment in a Novartis-sponsored Study and Are Benefiting From the Treatment as Judged by the Investigator · 188 trials list this drug (6 active)

—

not mapped

Observed

Gastrointestinal Stromal Tumor,Malignant Gastrointestinal Stromal Tumor

→ studied in

NCT06655246Phase 1 · recruiting

A Study of Ziftomenib in Combination With Imatinib in Patients With Advanced Gastrointestinal Stromal Tumors (GIST) · 188 trials list this drug (6 active)

—

Observed

→ studied in

NCT00015847Phase 2 · terminated

Imatinib Mesylate and Interferon Alfa in Treating Patients With Chronic Myelogenous Leukemia · 188 trials list this drug (6 active)

—

Observed

Gastrointestinal Stromal Tumor

→ studied in

NCT05385549Phase 2 · recruiting

5 Years of Adjuvant Imatinib in Patients With Gastrointestinal Stromal Tumor With a High Risk · 188 trials list this drug (6 active)

—

Observed

Chronic Myeloid Leukemia, BCR-ABL1 Positive,Chronic Myeloid Leukemia, Philadelphia Chromosome Positive, BCR-ABL1 Positive

→ studied in

NCT01751425Phase 1 · terminated

Ruxolitinib in Treating Participants With Chronic Myeloid Leukemia With Minimal Residual Disease While on Therapy With Tyrosine Kinase Inhibitors · 188 trials list this drug (6 active)

—

Observed

→ studied in

NCT01085617completed

Standard Chemotherapy with or Without Nelarabine or Rituximab in Treating Patients with Newly Diagnosed Acute Lymphoblastic Leukemia · 188 trials list this drug (6 active)

—

Observed

→ studied in

NCT00483366Phase 1 · completed

Imatinib Mesylate, Gemcitabine, and Capecitabine in Treating Patients With Advanced Solid Tumors · 188 trials list this drug (6 active)

—

Adult Solid Neoplasm

Observed